Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Trump is considering exempting certain "non-patented" pharmaceuticals from tariffs, although specific guidelines have not yet been released. The Intercept has withdrawn a liver drug from the US market, and Ocaliva, approved for primary biliary cholangitis in 2016, did not receive full approval last year. Merck is cutting 125 employees in the UK as it ends R&D work. AbbVie has extended exclusivity for its drug Rinvoq until 2037 with a generics settlement. Novo's headcount has increased by 81% in five years as revenue climbed. The FDA is reportedly preparing an order restricting Chinese drug licensing deals. Capsida has reported a patient death in a gene therapy trial. Novartis' BD team is busy with bolt-on deal promises for 2025. That's all for today's news in the Pharma and Biotech world. Thank you for listening!

Support the show